鲁索利替尼
骨髓纤维化
医学
重症监护医学
肿瘤科
内科学
骨髓
作者
Prithviraj Bose,Andrew Kuykendall,Carole B. Miller,Sandra Kurtin,Kyle Farina,Donald Harting,John Mascarenhas,Ruben A. Mesa
标识
DOI:10.1080/14656566.2023.2213435
摘要
Introduction Ruxolitinib has been the cornerstone of pharmacologic therapy for myelofibrosis for over a decade. However, the last several years have witnessed the regulatory approval of other Janus kinase (JAK) inhibitors for myelofibrosis, i.e. fedratinib, pacritinib, and US approval of momelotinib is widely anticipated in 2023.
科研通智能强力驱动
Strongly Powered by AbleSci AI